Exploratory Biomarker Analysis in Olaparib Maintenance Therapy for Ovarian Cancer
Study Overview
The L-MOCA trial has shown that olaparib maintenance therapy is effective and safe for Chinese patients with platinum-sensitive relapsed ovarian cancer. This study explores the impact of homologous recombination deficiency (HRD) and programmed cell death ligand 1 (PD-L1) expression on olaparib’s effectiveness.
Biomarker Assessment
HRD status was determined using the ACTHRD assay, and PD-L1 expression was assessed by the SP263 immunohistochemistry assay. The study included 225 patients and found that HRD-positive patients had a significantly longer median progression-free survival (PFS) compared to HRD-negative patients.
Key Findings
Positive PD-L1 expression was associated with reduced olaparib efficacy in patients with germline BRCA1/2 mutations but improved efficacy in patients with wild-type BRCA1/2.
Conclusion
HRD remains an effective biomarker for predicting olaparib efficacy in Asian patients with platinum-sensitive relapsed ovarian cancer. Additionally, PD-L1 expression can be a useful indicator for olaparib response in patients with different BRCA1/2 mutation statuses.
Trial Registration
Registered at May 23, 2018. PMID:38755585 | DOI:10.1186/s12916-024-03409-9
Clinical trials are essential for developing safe treatments, and our AI-driven platform, DocSym, integrates clinical standards and research for easy access by clinicians. In today’s healthcare environment, our mobile apps support scheduling, monitoring treatments, and telemedicine to streamline operations and improve patient care. By leveraging AI, clinics can enhance workflows and reduce paper routines for better patient outcomes. Learn more at aidevmd.com.
